儿童横纹肌肉瘤有限边界适形放疗的疗效与安全性:2期研究长期结果
5年无病生存率低危88%、中危76%、高危36%,全组5年局部失败累积发生率10.4%,肿瘤大小是局部失败的显著预测因素。尽管采用适形放疗,可测量功能缺陷的晚期毒性并不少见。
要点
- 5年局部失败累积发生率10.4%,肿瘤大小是显著预测因素。
- 5年无病生存率低危88%、中危76%、高危36%。
- 头颈部肿瘤白内障累积发生率35%,与晶状体剂量相关。
核心结论
- 有限边界适形光子放疗后长期局部失败率低,局部失败率较高与肿瘤较大相关。
- 尽管采用适形放疗,导致可测量功能缺陷的治疗相关毒性并不少见。
研究设计与样本
- 靶区包括1 cm扩展以覆盖显微病灶,处方剂量为该靶区36 Gy、大体残留病灶50.4 Gy。
- 化疗方案为长春新碱/放线菌素(n=6)、长春新碱/放线菌素/环磷酰胺(n=37)或以长春新碱/放线菌素/环磷酰胺为基础的联合方案(n=25)。
- 治疗后5年内以原发灶磁共振成像、全身[18F]氟脱氧葡萄糖正电子发射断层扫描和胸部计算机断层扫描进行评估。
主要发现
- 5年无病生存率低危(n=8)为88%、中危(n=37)为76%、高危(n=23)为36%(低危/中危 vs 高危 P ≤ .01)。
- 全队列5年局部失败累积发生率为10.4%,诊断时肿瘤大小是局部失败的显著预测因素(P < .01)。
- 头颈部原发肿瘤患者(n=31)白内障累积发生率为35%,风险与晶状体剂量相关(P = .0025)。
- 翼内肌和咬肌平均剂量>20 Gy时下颌功能障碍更严重(P = .013);骨性眼眶平均剂量>30 Gy后眼眶发育不良更常见(P = .041)。
- 泌尿生殖肿瘤患者的晚期毒性包括镜下血尿(14例中9例)、膀胱壁增厚(14例中10例)和阴道狭窄(5例中2例)。
关键数值与推荐
- 靶区处方剂量:显微病灶靶区36 Gy,大体残留病灶50.4 Gy。
- 靶区边界:原发灶外扩1 cm以覆盖显微病灶。
- 局部失败预测:诊断时肿瘤大小(P < .01)。
- 晶状体剂量与白内障风险相关(P = .0025);翼内肌和咬肌平均剂量>20 Gy与更严重下颌功能障碍相关(P = .013);骨性眼眶平均剂量>30 Gy与更常见眼眶发育不良相关(P = .041)。
临床怎么用
- 儿童横纹肌肉瘤采用有限边界适形光子放疗可获得较低长期局部失败率。
- 肿瘤较大者局部失败风险较高,需关注局部控制。
- 即使采用适形放疗,仍需关注晶状体、咀嚼肌和骨性眼眶剂量以降低晚期功能缺陷。
- 头颈部放疗后应监测白内障、下颌功能障碍和眼眶发育不良。
- 泌尿生殖肿瘤放疗后应监测血尿、膀胱壁增厚和阴道狭窄。
局限性
- 原文摘要未报告研究局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Our purpose was to assess disease outcomes and late toxicities in pediatric patients with rhabdomyosarcoma treated with conformal photon radiation therapy (RT). METHODS AND MATERIALS: Sixty-eight patients (median age, 6.9 years) were treated with conformal photon RT to the primary site on a prospective clinical trial. Target volumes included a 1-cm expansion encompassing microscopic disease. Prescribed doses were 36 Gy to this target volume and 50.4 Gy to gross residual disease. Chemotherapy consisted of vincristine/dactinomycin (n = 6), vincristine/dactinomycin/cyclophosphamide (n = 37), or vincristine/dactinomycin/cyclophosphamide-based combinations (n = 25). Patients were evaluated with primary-site magnetic resonance imaging, whole-body [18F]fluorodeoxyglucose positron emission tomography, and chest computed tomography for 5 years after treatment. RESULTS: Five-year disease-free survival was 88% for low-risk (n = 8), 76% for intermediate-risk (n = 37), and 36% for high-risk (n = 23) patients (P ≤ .01 for low risk/intermediate risk vs high risk). The cumulative incidence of local failure (LF) at 5 years for the entire cohort was 10.4%. Tumor size at diagnosis was a significant predictor of LF (P < .01). Patients with head and neck primary tumors (n = 31) had a 35% cumulative incidence of cataracts; the risk correlated with lens dose (P = .0025). Jaw dysfunction was more severe when the pterygoid and masseter muscles received a mean dose of >20 Gy (P = .013). Orbital hypoplasia developed more frequently after a mean bony orbit dose of >30 Gy (P = .041). Late toxicity in patients with genitourinary tumors included microscopic hematuria (9 of 14), bladder-wall thickening (10 of 14), and vaginal stenosis (2 of 5). CONCLUSIONS: Long-term LF rates were low, and higher rates correlated with larger tumors. Treatment-related toxicities resulting in measurable functional deficits were not infrequent, despite the conformal RT approach.
引用
- Tinkle CL, Pappo A, Wu J, et al. Efficacy and Safety of Limited-Margin Conformal Radiation Therapy for Pediatric Rhabdomyosarcoma: Long-Term Results of a Phase 2 Study. Int J Radiat Oncol Biol Phys. 2020. PMID: 31987969. doi:10.1016/j.ijrobp.2020.01.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。